Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BeatO
New Delhi, Delhi/NCT of Delhi/New Delhi region, Indiarickbeato.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Clinical results published in the American Diabetes Association and ATTD show that after three months on the program members experienced a 2.16% reduction in HbA1c, a 63 mg/dL reduction in fasting sugar level, an average weight loss of 2.5 kg, an 81.6% reduction in hypoglycemia incidents, and an 87.2 mg/dL reduction in postprandial sugar level. The program claims to be clinically proven for diabetes control and reversal.
- Therapeutic areas
- EndocrinologyCardiovascular
- Modalities
- DeviceDigital therapeuticNon-pharmacological therapy (digital care program and connected glucometer)
- Industry
- Digital Health Medical Devices
Beyond the preview
Go deeper on BeatO.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BeatO.